This study evaluated whether oral nalbuphine extended release (ER) reduces cough and improves patient-reported outcomes in patients with idiopathic pulmonary fibrosis (IPF) and chronic cough.
JAMA (Journal of the American Medical Association) published a clinical update in Research Highlights on 24 Mar 2026.
The item focuses on Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough Research Summary.
Review the original article for the full source wording and details.